232 related articles for article (PubMed ID: 26085606)
1. Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.
Toledo JB; Bjerke M; Chen K; Rozycki M; Jack CR; Weiner MW; Arnold SE; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
Neurology; 2015 Jul; 85(2):144-53. PubMed ID: 26085606
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
3. A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
Baumeister H; Vogel JW; Insel PS; Kleineidam L; Wolfsgruber S; Stark M; Gellersen HM; Yakupov R; Schmid MC; Lüsebrink F; Brosseron F; Ziegler G; Freiesleben SD; Preis L; Schneider LS; Spruth EJ; Altenstein S; Lohse A; Fliessbach K; Vogt IR; Bartels C; Schott BH; Rostamzadeh A; Glanz W; Incesoy EI; Butryn M; Janowitz D; Rauchmann BS; Kilimann I; Goerss D; Munk MH; Hetzer S; Dechent P; Ewers M; Scheffler K; Wuestefeld A; Strandberg O; van Westen D; Mattsson-Carlgren N; Janelidze S; Stomrud E; Palmqvist S; Spottke A; Laske C; Teipel S; Perneczky R; Buerger K; Schneider A; Priller J; Peters O; Ramirez A; Wiltfang J; Heneka MT; Wagner M; Düzel E; Jessen F; Hansson O; Berron D
Brain; 2024 Jul; 147(7):2400-2413. PubMed ID: 38654513
[TBL] [Abstract][Full Text] [Related]
4. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.
Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P
J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
Davatzikos C; Xu F; An Y; Fan Y; Resnick SM
Brain; 2009 Aug; 132(Pt 8):2026-35. PubMed ID: 19416949
[TBL] [Abstract][Full Text] [Related]
6. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
7. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
[TBL] [Abstract][Full Text] [Related]
8. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
Risacher SL; McDonald BC; Tallman EF; West JD; Farlow MR; Unverzagt FW; Gao S; Boustani M; Crane PK; Petersen RC; Jack CR; Jagust WJ; Aisen PS; Weiner MW; Saykin AJ;
JAMA Neurol; 2016 Jun; 73(6):721-32. PubMed ID: 27088965
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
[TBL] [Abstract][Full Text] [Related]
10. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
[TBL] [Abstract][Full Text] [Related]
11. Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease.
Dodge HH; Zhu J; Harvey D; Saito N; Silbert LC; Kaye JA; Koeppe RA; Albin RL;
Alzheimers Dement; 2014 Nov; 10(6):690-703. PubMed ID: 25022534
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness of magnetic resonance imaging and neuropsychological assessment in memory clinic patients.
Schmand B; Rienstra A; Tamminga H; Richard E; van Gool WA; Caan MW; Majoie CB
J Alzheimers Dis; 2014; 40(2):409-18. PubMed ID: 24473187
[TBL] [Abstract][Full Text] [Related]
13. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
14. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
[TBL] [Abstract][Full Text] [Related]
15. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.
Auning E; Selnes P; Grambaite R; Šaltytė Benth J; Haram A; Løvli Stav A; Bjørnerud A; Hessen E; Hol PK; Muftuler løndalen A; Fladby T; Aarsland D
Acta Psychiatr Scand; 2015 Feb; 131(2):139-47. PubMed ID: 25346330
[TBL] [Abstract][Full Text] [Related]
16. Impact of analgesics on executive function and memory in the Alzheimer's Disease Neuroimaging Initiative Database.
Doan L; Choi D; Kline R;
Scand J Pain; 2017 Oct; 17():408-417. PubMed ID: 29103867
[TBL] [Abstract][Full Text] [Related]
17. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
18. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
20. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
